Autoantibodies Neutralizing Type I IFNs Underlie West Nile Virus Encephalitis in ∼40% of Patients

Mosquito-borne West Nile virus (WNV) infection is benign in most individuals but can cause encephalitis in <1% of infected individuals. We show that ∼35% of patients hospitalized for WNV disease (WNVD) in six independent cohorts from the EU and USA carry auto-Abs neutralizing IFN-α and/or -ω. The prevalence of these antibodies is highest in patients with encephalitis (∼40%), and that in individuals with silent WNV infection is as low as that in the general population. The odds ratios for WNVD in individuals with these auto-Abs relative to those without them in the general population range from 19.0 (95% CI 15.0-24.0, P value <10-15) for auto-Abs neutralizing only 100 pg/ml IFN-α and/or IFN-ω to 127.4 (CI 87.1-186.4, P value <10-15) for auto-Abs neutralizing both IFN-α and IFN-ω at a concentration of 10 ng/ml. These antibodies block the protective effect of IFN-α in Vero cells infected with WNV in vitro. Auto-Abs neutralizing IFN-α and/or IFN-ω underlie ∼40% of cases of WNV encephalitis.

Citing Articles

Serum levels of neurofilament light chain and glial fibrillary acidic protein correlate with disease severity in patients with West Nile virus infection.

Dinoto A, Pacenti M, Mariotto S, Abate D, Lisi V, Satto S Emerg Microbes Infect. 2025; 14(1):2447606.

PMID: 39945666 PMC: 11849020. DOI: 10.1080/22221751.2024.2447606.

West Nile Virus: An Update Focusing on Southern Europe.

Carrasco L, Utrilla M, Fuentes-Romero B, Fernandez-Novo A, Martin-Maldonado B Microorganisms. 2025; 12(12.

PMID: 39770826 PMC: 11677777. DOI: 10.3390/microorganisms12122623.

The monogenic landscape of human infectious diseases.

Boisson-Dupuis S, Bastard P, Beziat V, Bustamante J, Cobat A, Jouanguy E J Allergy Clin Immunol. 2024; 155(3):768-783.

PMID: 39724971 PMC: 11875930. DOI: 10.1016/j.jaci.2024.12.1078.

A common form of dominant human IFNAR1 deficiency impairs IFN-α and -ω but not IFN-β-dependent immunity.

Al Qureshah F, Le Pen J, de Weerd N, Moncada-Velez M, Materna M, Lin D J Exp Med. 2024; 222(2).

PMID: 39680367 PMC: 11648951. DOI: 10.1084/jem.20241413.

A Novel Heterozygous NFKB2 Variant in a Multiplex Family with Common Variable Immune Deficiency and Autoantibodies Against Type I IFNs.

Baran A, Atilgan Lulecioglu A, Gao L, Yazici Y, Demirel F, Metin A J Clin Immunol. 2024; 45(1):48.

PMID: 39579251 PMC: 11821294. DOI: 10.1007/s10875-024-01843-1.

References

Patel H, Sander B, Nelder M . Long-term sequelae of West Nile virus-related illness: a systematic review. Lancet Infect Dis. 2015; 15(8):951-9. DOI: 10.1016/S1473-3099(15)00134-6. View

Melnick J, Paul J, RIORDAN J, BARNETT V, GOLDBLUM N, ZABIN E . Isolation from human sera in Egypt of a virus apparently identical to West Nile virus. Proc Soc Exp Biol Med. 1951; 77(4):661-5. DOI: 10.3181/00379727-77-18884. View

Messacar K, Cree-Green M, Lovell M, Anderson M, Dominguez S . Severe Neuroinvasive West Nile Virus Infection in a Child with Undiagnosed Addison's Disease. IDCases. 2014; 1(3):29-31. PMC: 4131694. DOI: 10.1016/j.idcr.2014.04.001. View

Zhang Q, Bastard P, Cobat A, Casanova J . Human genetic and immunological determinants of critical COVID-19 pneumonia. Nature. 2022; 603(7902):587-598. PMC: 8957595. DOI: 10.1038/s41586-022-04447-0. View

ODriscoll M, Ribeiro Dos Santos G, Wang L, Cummings D, Azman A, Paireau J . Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2020; 590(7844):140-145. DOI: 10.1038/s41586-020-2918-0. View

Samuel M, Diamond M . Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol. 2005; 79(21):13350-61. PMC: 1262587. DOI: 10.1128/JVI.79.21.13350-13361.2005. View

Vinh D, Abel L, Bastard P, Cheng M, Condino-Neto A, Gregersen P . Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β. J Clin Immunol. 2021; 41(7):1425-1442. PMC: 8186356. DOI: 10.1007/s10875-021-01068-6. View

Casanova J, Abel L . Mechanisms of viral inflammation and disease in humans. Science. 2021; 374(6571):1080-1086. PMC: 8697421. DOI: 10.1126/science.abj7965. View

Tsai T, Popovici F, Cernescu C, Campbell G, Nedelcu N . West Nile encephalitis epidemic in southeastern Romania. Lancet. 1998; 352(9130):767-71. DOI: 10.1016/s0140-6736(98)03538-7. View

10.

Carson P, Borchardt S, Custer B, Prince H, Dunn-Williams J, Winkelman V . Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999-2008. Emerg Infect Dis. 2012; 18(4):684-6. PMC: 3309699. DOI: 10.3201/eid1804.111313. View

11.

Casanova J, Abel L . From rare disorders of immunity to common determinants of infection: Following the mechanistic thread. Cell. 2022; 185(17):3086-3103. PMC: 9386946. DOI: 10.1016/j.cell.2022.07.004. View

12.

Bastard P, Michailidis E, Hoffmann H, Chbihi M, Le Voyer T, Rosain J . Auto-antibodies to type I IFNs can underlie adverse reactions to yellow fever live attenuated vaccine. J Exp Med. 2021; 218(4). PMC: 7871457. DOI: 10.1084/jem.20202486. View

13.

Hale B . Autoantibodies targeting type I interferons: Prevalence, mechanisms of induction, and association with viral disease susceptibility. Eur J Immunol. 2023; 53(6):e2250164. DOI: 10.1002/eji.202250164. View

14.

Schoggins J, Wilson S, Panis M, Murphy M, Jones C, Bieniasz P . A diverse range of gene products are effectors of the type I interferon antiviral response. Nature. 2011; 472(7344):481-5. PMC: 3409588. DOI: 10.1038/nature09907. View

15.

Styer L, Kent K, Albright R, Bennett C, Kramer L, Bernard K . Mosquitoes inoculate high doses of West Nile virus as they probe and feed on live hosts. PLoS Pathog. 2007; 3(9):1262-70. PMC: 1976553. DOI: 10.1371/journal.ppat.0030132. View

16.

Pozzetto B, Mogensen K, Tovey M, GRESSER I . Characteristics of autoantibodies to human interferon in a patient with varicella-zoster disease. J Infect Dis. 1984; 150(5):707-13. DOI: 10.1093/infdis/150.5.707. View

17.

Zhang Q, Pizzorno A, Miorin L, Bastard P, Gervais A, Le Voyer T . Autoantibodies against type I IFNs in patients with critical influenza pneumonia. J Exp Med. 2022; 219(11). PMC: 9485705. DOI: 10.1084/jem.20220514. View

18.

Sutinen J, Fell D, Sander B, Kulkarni M . Comorbid conditions as risk factors for West Nile neuroinvasive disease in Ontario, Canada: a population-based cohort study. Epidemiol Infect. 2022; 150:e103. PMC: 9171902. DOI: 10.1017/S0950268822000887. View

19.

Petersen L, Brault A, Nasci R . West Nile virus: review of the literature. JAMA. 2013; 310(3):308-15. PMC: 4563989. DOI: 10.1001/jama.2013.8042. View

20.

Solomon T . Flavivirus encephalitis. N Engl J Med. 2004; 351(4):370-8. DOI: 10.1056/NEJMra030476. View